Liquid biopsies, comprising the noninvasive analysis of circulating tumor-derived material
(the 'tumor circulome'), represent an innovative tool in precision oncology to overcome …

The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with
considerable potential to improve clinical outcomes across multiple cancer types, including …

The possibility to analyse the tumour genetic material shed in the blood is undoubtedly one
of the main achievements of translational research in the latest years. In the modern clinical …

Simple Summary The gold standard for detecting cancer and profiling tumors is tissue
biopsies. Despite this, tissue biopsies have been associated with many limitations leading to …

Assessment of cell free DNA (cfDNA) and RNA (cfRNA), circulating tumor cells (CTC) and
extracellular vesicles (EV) in blood or other bodily fluids can enable early cancer detection …

Abstract Purpose: Circulating tumor DNA (ctDNA) has been suggested as a major
prognostic factor in resected stage-III colon cancer. We analyzed ctDNA of patients …

Abstract Analysis of liquid biopsies and the identification of non-invasive biomarkers for the
diagnosis and prognosis of solid tumors has grown exponentially over the last few years …

Body fluids are constantly replenished with a population of genetically diverse cell-free DNA
(cfDNA) fragments, representing a vast reservoir of information reflecting real-time changes …

Simple Summary During the development and progression of lung tumors, processes such
as necrosis and vascular invasion shed tumor cells or cellular components into various fluid …

Circulating cell-free DNA (cfDNA) is rapidly transitioning from discovery research to an
important tool in clinical decision making. However, the lack of harmonization of preanalytic …